Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential for shorter treatment for HIV/HCV co-infected people, according to a presentation last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Direct-acting antiviral agents that target different steps of the HCV lifecycle have ushered in a new era of treatment. While interferon-free, all-oral regimens are on the horizon, many people with chronic hepatitis C have advancing liver disease and cannot wait. Although HIV-positive people with hepatitis C experience more rapid liver disease progression, they will have to wait longer for approval of interferon-free combinations, as new agents are typically approved for HCV monoinfected people first.
View abstract 40LB on the conference website.
A webcast of the session in which this research was presented, Advances in Hepatitis Therapy, is available on the conference website.